Page last updated: 2024-11-05

1-(2-(2,4-dichlorophenyl)-2-hydroxyethyl)-1h-imidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-(2-(2,4-dichlorophenyl)-2-hydroxyethyl)-1H-imidazole: RN given refers to parent cpd; structure given in first source; principal transformation product of imazalil [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID32238
CHEMBL ID1327
SCHEMBL ID4817509
MeSH IDM0173475

Synonyms (82)

Synonym
imidazole-1-ethanol, alpha-(2,4-dichlorophenyl)-
n-(beta-(2,4-dichlorophenyl)-beta-hydroxyethyl)imidazole
brn 0617090
1h-imidazole-1-ethanol, alpha-(2,4-dichlorophenyl)-
benzyl alcohol, 2,4-dichloro-alpha-(1-imidazolylmethyl)-
r 14821
einecs 246-042-5
alpha-(2,4-dichlorophenyl)-1h-imidazole-1-ethanol
t 824
smr000066401
MLS000056514 ,
D3629
1-[2-(2,4-dichlorophenyl)-2-hydroxyethyl]imidazole
1-(2,4-dichlorophenyl)-2-(1-imidazolyl)ethanol
24155-42-8
1-(2,4-dichlorophenyl)-2-(1h-imidazol-1-yl)ethanol
1-(2,4-dichlorophenyl)-2-imidazol-1-ylethanol
CHEMBL1327 ,
AKOS000121602
A18508
1-(2,4-dichlorophenyl)-2-(1h-imidazol-1-yl)ethan-1-ol
1-(2,4-dichloro-phenyl)-2-imidazol-1-yl-ethanol
HMS2166D10
uk 11147
ec 246-042-5
cp4am80t68 ,
1-(2-(2,4-dichlorophenyl)-2-hydroxyethyl)-1h-imidazole
unii-cp4am80t68
FT-0605479
PS-3676
HMS3315K04
fi-7001
tioconazole impurity d [ep impurity]
r-14821
uk-11147
.alpha.-(2,4-dichlorophenyl)imidazole-1-ethanol
econazole nitrate impurity a [ep impurity]
(1rs)-1-(2,4-dichlorophenyl)-2-(1h-imidazol-1-yl)ethanol
(+/-)-.alpha.-(2,4-dichlorophenyl)-1h-imidazole-1-ethanol
fenticonazole nitrate impurity a [ep impurity]
miconazole nitrate impurity a [ep impurity]
econazole impurity a [ep impurity]
miconazole impurity a [ep impurity]
t-824
.alpha.-(2,4-dichlorophenyl)-1h-imidazole-1-ethanol
1-(2,4-dichlorophenyl)-2-(1h-imidazol-1-yl)ethanol, (+/-)-
deschlorobenzyl econazole
1-(2,4-dichlorophenyl)-2-(1h-imidazol-1-yl)-ethanol
UKVLTPAGJIYSGN-UHFFFAOYSA-N
1-(2,4-dichlorophenyl)-1-hydroxy-2-(imidazol-1-yl)-ethane
1-(2',4'-dichlorophenyl)-2-(n-imidazolyl)-ethanol
1-(2,4-dichloro-phenyl)-2-(1-imidazolyl) ethanol
2,4-dichloro-alpha-[(1-imidazolyl)methyl]benzyl alcohol
SCHEMBL4817509
mfcd00044708
AKOS016842478
W-107348
AC-26453
alpha-(2,4-dichlorophenyl)-(1h)-imidazole-1-ethanol
DTXSID3074737
STL452904
bdbm50051838
1-(2,4-dichloro-phenyl)-2-imidazol-1-yl-ethanol, aldrichcpr
|a inverted exclamation mark-(2,4-dichlorophenyl)-1h-imidazole-1-ethanol
Z56969300
1-(2,4-dichlorophenyl)-2-(1h-imidazole-1-yl)-1-ethanol
SY002118
imazalil metabolite
r014821 ,
BCP11459
(+/-)-1-(2,4-dichlorophenyl)-2-(1h-imidazol-1-yl)ethanol
Q27275605
(1-formyl-cyclopropyl)-nhboc
SB48780
rac-1-(2,4-dichlorophenyl)-2-(1-imidazolyl)ethanol
EN300-17614
isoconazole impurity a (fenticonazole impurity a, econazole nitrate impurity a)
miconazole impurity a
enilconazole impurity e
CS-W010172
1h-imidazole-1-ethanol, ?-(2,4-dichlorophenyl)-
sd-215748
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency1.77830.28189.721235.4813AID2326
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency89.12510.035520.977089.1251AID504332
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Indoleamine 2,3-dioxygenase 1Homo sapiens (human)IC50 (µMol)130.00000.05373.075710.0000AID1184069
Alpha-2C adrenergic receptorHomo sapiens (human)Ki15.13560.00030.483410.0000AID1232265
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-2C adrenergic receptorHomo sapiens (human)EC50 (µMol)338.84400.00050.55416.7100AID1232266
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (33)

Processvia Protein(s)Taxonomy
regulation of activated T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell tolerance inductionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of chronic inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of type 2 immune responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
female pregnancyIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic process to kynurenineIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
response to lipopolysaccharideIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of interleukin-10 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of interleukin-12 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
multicellular organismal response to stressIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
kynurenic acid biosynthetic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
swimming behaviorIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
'de novo' NAD biosynthetic process from tryptophanIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
electron transfer activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
heme bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
indoleamine 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
metal ion bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytosolIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
smooth muscle contractile fiberIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
stereocilium bundleIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
cytoplasmIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1600160Antifungal activity against azole-resistant Candida tropicalis assessed as reduction in fungal growth incubated for 48 hrs by broth microdilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery of new azoles with potent activity against Candida spp. and Candida albicans biofilms through virtual screening.
AID113963Anticonvulsant activity was evaluated by the maximal electroshock test in mice, administered orally1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Synthesis and anticonvulsant activity of N-(benzoylalkyl)imidazoles and N-(omega-phenyl-omega-hydroxyalkyl)imidazoles.
AID1232265Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis2015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Cell-based and virtual fragment screening for adrenergic α2C receptor agonists.
AID1600163Antifungal activity against azole-susceptible Candida parapsilosis ATCC 90018 assessed as reduction in fungal growth incubated for 48 hrs by broth microdilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery of new azoles with potent activity against Candida spp. and Candida albicans biofilms through virtual screening.
AID117081Lethal dose in mice determined after intraperitoneal administration.1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Synthesis and anticonvulsant activity of N-(benzoylalkyl)imidazoles and N-(omega-phenyl-omega-hydroxyalkyl)imidazoles.
AID1232267Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis relative to UK143042015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Cell-based and virtual fragment screening for adrenergic α2C receptor agonists.
AID1232266Agonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as induction of cytoplasmic calcium mobilization measured for 40 secs by fluorometric analysis2015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Cell-based and virtual fragment screening for adrenergic α2C receptor agonists.
AID113962Anticonvulsant activity by the maximal electroshock test in mice by intraperitoneal administration1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Synthesis and anticonvulsant activity of N-(benzoylalkyl)imidazoles and N-(omega-phenyl-omega-hydroxyalkyl)imidazoles.
AID1600162Antifungal activity against azole-susceptible Candida krusei ATCC 6258 assessed as reduction in fungal growth incubated for 48 hrs by broth microdilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery of new azoles with potent activity against Candida spp. and Candida albicans biofilms through virtual screening.
AID1600161Antifungal activity against azole-susceptible Candida albicans ATCC 90028 assessed as reduction in fungal growth incubated for 48 hrs by broth microdilution method2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery of new azoles with potent activity against Candida spp. and Candida albicans biofilms through virtual screening.
AID1184069Inhibition of IDO1 (unknown origin) using L-tryptophan substrate incubated for 60 mins in presence of 0.01% Triton-X by HPLC2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID1184074Solubility of the compound in pH 6.5 phosphate buffer containing 5% DMSO2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (20.00)18.7374
1990's0 (0.00)18.2507
2000's1 (10.00)29.6817
2010's6 (60.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.84 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]